Board Member & chief executive officer
Prior to Nirogy, Vincent was the Senior Director at Karyopharm where he discovered the drug, XPOVIO® (Selinexor) currently approved for multiple myeloma and lymphoma indications. Dr. Sandanayaka began his career at Pfizer and moved through the ranks with increasing responsibility at AstraZeneca, DeCode Genetics/Amgen, Epix Pharmaceuticals, and Karyopharm. His efforts led to six novel compounds that were investigated in clinical trials spanning immunology, cardiovascular, neuroscience, and oncology therapeutic areas.
Vincent completed a post-doctoral fellowship at Emory University, obtained Ph.D. in Synthetic Organic Chemistry from Wayne State University, and holds a B.Sc (Special) degree from the University of Peradeniya, Sri Lanka.